Table 3.
Baseline characteristics of patients showing ATDH (N=35)
| Characteristics | Findings |
|---|---|
| Age, years+++ | 48.1±19 |
| Female sex+,sex ratio (M/F) | 18(51.4),0.9 |
| Classification of ATDH+ | |
| Hepatocellular hepatitis | 23(65.7) |
| Cholestatic hepatitis | 4(11.4) |
| Mixed hepatitis | 8(22.9) |
| Time of development of the ATDH++ (days) | 19(10-25) |
| Early * (<15 days) | 14(40) |
| Delayed* (>15 days) | 21(60) |
| Normalization of liver function tests (days) | 18(10-30) |
| Symptoms of hepatotoxicity+ | |
| Asthenia | 10(28.6) |
| Nausea | 11(31.4) |
| Abdominal pain | 8(22.9) |
| Jaundice | 8(22.9) |
| Pruritus | 6(17.1) |
| Fever | 7(20) |
| Anorexia | 10(28.6) |
| Duration of treatment discontinuation++(day) | 18(11-30) |
| Doses (mg/kg/day) | |
| INH | 4.7(4.4-5.3) |
| RIF | 8.2(7.5-10) |
| PZA | 25.4(23.5-28.6) |
+
No (%)
++
median range
+++
mean ± SD